Format

Send to

Choose Destination
Trends Pharmacol Sci. 2012 Jul;33(7):405-12. doi: 10.1016/j.tips.2012.04.002. Epub 2012 May 25.

Integrins as therapeutic targets.

Author information

1
Department of Cellular Pharmacology - Oncology Platform, Merck KGaA, Frankfurterstrasse 250, 64271 Darmstadt, Germany. Simon.L.Goodman@merckgroup.com

Abstract

Integrins are a large family of molecules that are central regulators in multicellular biology. They orchestrate cell-cell and cell-extracellular matrix (ECM) adhesive interactions from embryonic development to mature tissue function. Diverse human pathologies involve integrin adhesion, including thrombotic diseases, inflammation, cancer, fibrosis and infectious diseases. Integrins are exciting pharmacological targets because they are exposed on the cell surface and are sensitive to pharmacological blockade, but the scale of current efforts involving integrin therapeutics continues to surprise. Several therapeutics targeting integrins are effective drugs: five have been approved for use in clinic, with combined sales of over $1.5 billion in 2010 (based on company reports from that year). We gathered information from three major drug-trial databases and found that ∼260 anti-integrin drugs have entered clinical trials. Here we overview integrins as drug targets and focus on cancer.

PMID:
22633092
DOI:
10.1016/j.tips.2012.04.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center